

HaloDx and Keen Eye Partner to Empower Immunoscore® with Artificial Intelligence

Marseille & Paris, France, November 8, 2018 – HaloDx, an immuno-oncology diagnostic company pioneering the immunological diagnosis of cancers with Immunoscore® and Keen Eye, an innovative company specialized in image analysis technologies based on artificial intelligence announced today a strategic partnership to develop a cloud-based platform and applications. The partnership will create the very first cloud-based computational pathology system supported by the high medical value of Immunoscore® and directed to patients benefit.

This partnership will leverage Keen Eye and HaloDx combined technologies for image analysis using artificial intelligence and cloud architecture. The software solution will be first deployed to support the services offering of HaloDx toward pathologists and oncologists, primarily to perform Immunoscore® Colon, a test for which a high medical utility has been recently demonstrated in the Lancet journal¹. The solution is also intended to provide a robust solution for Companion Diagnostic development, validation and commercialization for HaloDx pharma and biotech partners.

This partnership will also accelerate the deployment and commercialization of Keen Eye's products and services toward the *in vitro* diagnostics market, both in Europe and United States. At the moment, the company's technology is being developed for two kinds of application: 1) to empower physicians to make more accurate, standardized diagnoses using consistent, AI-driven algorithms, and 2) to accelerate drug development with pharmaceutical companies, in preclinical and clinical studies, by increasing analytical capabilities and automating certain tasks.

"This partnership with Keen Eye is exemplary as it offers a high complementarity in term of scientific, technical and regulatory expertise but also in term of field and market access", said Vincent FERT, CEO and co-founder of HaloDx. He added "Both teams are keen to start as they are very conscious of the impact they can make on patient care with the combination of their respective technologies"

"We are delighted to initiate this strategic partnership with HaloDx, especially in a moment where the impact of immuno-oncology on patients' life has been awarded this year with the highest honors", commented Sylvain Berlemont, CEO and founder of Keen Eye. He added "We are eager to bring Immunoscore® to another scale, leveraging on the latest cloud and machine learning technology".

¹ International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study; Pagès et al. The Lancet P2128-2139, May 26, 2018.

About HalioDx

The Immune Response to Cancer Diagnostics

HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies. Immunoscore® proprietary technology, pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with sophisticated algorithm and advanced imaging analysis enabling extraction of spatially-organized tissue molecular information. Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression. HalioDx collaborates with renowned international clinical groups to support clinical utility and ensure rigorous performance validation of its assays in selected cancer indications.

HalioDx has an experienced team of more than 130 employees, a CLIA-certified laboratory and compliant facilities to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. The company co-founded the European immunology cluster Marseille Immunopôle (MI).

For more information, please visit our websites www.halioldx.com and www.immunoscore-colon.com and follow the company on Twitter [@HalioDx](https://twitter.com/HalioDx).

Contacts

HalioDx SAS

Vincent Fert

President and CEO

+ 33 (0)4 91 29 30 90

vincent.fert@halioldx.com

ATCG Press

Marie Puvieux (France)

Mob: +33 (0)6 10 54 36 72

Céline Voisin (ROW)

Mob: +33 (0)6 62 12 53 39

halioldx@atcg-partners.com

[Twitter: twitter.com/halioldx](https://twitter.com/halioldx)